Esophageal Cancer Clinical Trials in Salt Lake City, Utah
4 studies are recruiting for esophageal cancer in Salt Lake City, Utah right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah
- Locations
- 39 in total
- Run by
- Eli Lilly and Company
-
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansio…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Utah Cancer Specialists, Salt Lake City, Utah
- Locations
- 54 in total
- Run by
- Merus B.V.
-
Hypoxia Imaging for Esophageal Cancer to Guide Personalized Radiation Therapy
This is a Phase I trial evaluating the safety of personalized radiation therapy based on levels of hypoxia identified on FMISO-PET and MRI. All patients will receive a baseline FMISO positron emission tomography (PET) and MRI to identify levels of hypoxia. Patients with tumor hypoxia will receive a…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Huntsman Cancer Institute, Salt Lake City, Utah
- Run by
- University of Utah
-
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curat…
- Stage
- Phase 1
- Ages
- 18 to 80
- Site
- Utah Cancer Specialists (site 203), Salt Lake City, Utah
- Locations
- 15 in total
- Run by
- VM Oncology, LLC
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.